

BROOK'S
CLINICAL PEDIATRIC
ENDOCRINOLOGY

7TH EDITION

Edited by
Mehul T. Dattani
Charles G.D. Brook



WILEY

Brook's Clinical Pediatric Endocrinology

Brook's Clinical Pediatric Endocrinology

Seventh Edition

Edited by

*Mehul T. Dattani, MD FRCP FRCPCH
Professor and Head of Paediatric Endocrinology
Genetics and Genomic Medicine Programme
UCL Great Ormond Street Institute of Child Health
Great Ormond Street Hospital for Children NHS Foundation Trust
London, UK*

*Charles G. D. Brook, MA MD FRCP
Emeritus Professor of Paediatric Endocrinology
University College London
London, UK*

WILEY

This edition first published 2020
© 2020 John Wiley & Sons Ltd

Edition History
Wiley-Blackwell (6e, 2009)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Mehul T. Dattani and Charles G. D. Brook to be identified as the author(s) of the editorial material in this work has been asserted in accordance with law.

Registered Office(s)
John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office
9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Dattani, Mehul T., editor. | Brook, C. G. D. (Charles Groves Darville), editor.
Title: Brook's clinical pediatric endocrinology / edited by Mehul T. Dattani, Charles G.D. Brook.
Other titles: Clinical pediatric endocrinology
Description: 7th edition. | Hoboken, NJ : Wiley-Blackwell, 2020. | Preceded by Brook's clinical pediatric endocrinology / edited by Charles G.D. Brook, Peter E. Clayton, Rosalind S. Brown. 6th ed. 2009. | Includes bibliographical references and index. |
Identifiers: LCCN 2019003272 (print) | LCCN 2019003907 (ebook) | ISBN 9781119152699 (Adobe PDF) | ISBN 9781119152705 (ePub) | ISBN 9781119152682 (hardback)
Subjects: | MESH: Endocrine System Diseases | Adolescent | Child | Infant
Classification: LCC RJ418 (ebook) | LCC RJ418 (print) | NLM WS 335 | DDC 618.92/4--dc23
LC record available at <https://lcn.loc.gov/2019003272>

Cover Design: Wiley
Cover Image: © VikiVector/Getty Images

Set in 10/12pt Warnock by SPi Global, Pondicherry, India

10 9 8 7 6 5 4 3 2 1

Contents

List of Contributors	<i>xix</i>
Preface	<i>xxiii</i>
About the Companion Website	<i>xxv</i>

1 Genetics and Genomics	1
<i>Anu Bashamboo and Ken McElreavey</i>	
Introduction	1
Basic Concepts in Human Genetics and Genomics	1
Genes and Chromosomes	1
Regulation of Gene Expression	4
RNA Editing	4
Classes of RNA Molecules and their Functions	4
MicroRNAs, Small Interfering RNAs, and Piwi-interacting RNAs	5
LncRNAs	6
Other Small ncRNA Classes	7
Gene Mutations and Inheritance	7
Classes of Gene Mutations	7
Patient and Family History	8
Mendelian Inheritance Patterns	8
Non-Mendelian Inheritance Patterns	9
Common Disorders with Complex Inheritance Patterns	10
Uniparental Disomy	11
Penetrance and Expressivity	11
Human Populations and Genetic Variation	12
Overview of Human Genetic Variation	12
Allele Frequencies Differ in Different Populations	12
Copy Number Variation (CNV)	13
Epigenetics	14
Epigenetic Mechanisms	14
Genomic Imprinting	14
Transgenerational and Multigenerational Epigenetic Inheritance	15
Advances in Genomic Analysis	15
Familial Linkage Analysis and GWAS Studies	15
Advances in Nucleic Acid Sequencing	16
NGS Protocols	17
Whole Genome (WGS) and Whole Exome Sequencing (WES)	17
Establishing Variant Causality	19
Dissecting Pathogenic from Non-Pathogenic Variants	19
Genome Editing as a Powerful Tool for Establishing Causality	22

The Age of Precision Medicine	24
Clinical Guidelines	24
Acknowledgments	25
Glossary of Terms	25
Further Reading	29

2 Measuring Hormones 31

Gerhard Binder

Introduction	31
Hormone Assays	31
Assay Validity	33
Technical Pitfalls When Measuring Hormones	36
Clinical Assay Validity	38
Stimulation Tests, Suppression Tests and Profiles	42
Optimal Clinical Use of Hormone Tests	44
Acknowledgements	44
References	44

3 Fetal Endocrinology 47

Harshini Katugampola, Evelien F. Gevers, and Mehul T. Dattani

Introduction	48
Transplacental Passage of Hormones	48
Development of Fetal Endocrine Systems	50
Pituitary Development	50
Adrenal Development	55
Thyroid Development	62
Gonadal Development	66
Disorders of Sex Development (see Chapter 4)	69
Development of the Fetal Autonomic Nervous System	69
Development of the Endocrine Pancreas	71
Development of Pancreatic Endocrine Function	73
Development of the Parathyroid/Calcitonin System	75
Endocrine Regulation of Fetal Growth	78
Neutralization of Hormone Activity in the Fetus	82
Limitation of Hormone Secretion	82
Production of Inactive Hormone Metabolites	83
Delayed Expression or Neutralization of Receptor Response	83
Plasticity of Fetal Endocrine Systems	84
Fetal Adaptations for Transition to Extrauterine Life	85
Cortisol	86
Catecholamines	87
Thermogenesis	87
Calcium Homeostasis	87
Glucose Homeostasis	88
Other Endocrine Adaptations	88
Frontiers in Fetal and Neonatal Endocrinology	89
References	90

4 Disorders of Sex Development 105

Martine Cools and Birgit Köhler

Normal Sex Development	105
Terminology	106
Causes of DSD	107

Impaired Gonadal Development	108
XY Individuals	108
XX individuals	111
Numerical Abnormalities of the Sex Chromosomes	112
Disturbances of Testicular Hormone Production or Action	113
Impaired Biosynthesis	113
Impaired Testosterone Action	114
Virilization of an XX Individual	116
Management of DSD	118
Initial Evaluation and Diagnostic Approach	118
Examination	119
Hormonal Workup	119
Genetic Tests	121
Sex Assignment, Gender Development, Early Genital Surgery and Disclosure of the Condition	121
Clinical Management	122
Gonadal Tumour Risk and Indications for Gonadectomy	123
Information and Support for Parents Having a Baby with DSD	124
Information and Support for Children and Adolescents	124
Transition	124
Adult Outcome	125
Other Examples of XY DSD	126
Hypospadias	126
Cryptorchidism	126
Persistent Müllerian Duct Syndrome	126
Future Perspectives	127
References	127
Weblinks	131
5 Disorders of Hypothalamo-Pituitary Axis	133
<i>Hoong-Wei Gan, Kyriaki-Sandy Alatzoglou, and Mehul T. Dattani</i>	
Introduction	133
The Hypothalamo-Pituitary Neuroendocrine Axis	134
Hypothalamo-Pituitary Development	134
Hypothalamo-Pituitary Organogenesis	135
Cell Differentiation, Organization and Plasticity in the Anterior Pituitary	136
Early Developmental Genes and Transcription Factors	137
Terminal Cell Differentiation	143
Congenital Disorders of Hypothalamo-Pituitary Development	144
Combined Pituitary Hormone Deficiencies (CPHD)	144
Isolated Pituitary Hormone Deficiencies	152
Acquired Disorders of Hypothalamo-Pituitary Dysfunction	155
Central Nervous System (CNS) Tumours	155
Infiltrative and Inflammatory Disorders	166
Traumatic Brain Injury	168
CNS Infection	169
Haemochromatosis	170
Psychosocial Deprivation	171
Investigation of Hypopituitarism	172
Management of Hypopituitarism	173
Conclusion	174
References	174

6 Disorders of Growth	199
<i>P.G. Murray and P.E. Clayton</i>	
Normal Growth	200
Physiology of Growth	201
Short Stature	205
Aetiology of Growth Impairment	205
Growth Hormone Deficiency	205
Biochemical Evaluation of Suspected GH Deficiency	206
Neuroimaging	208
Genetic Studies	208
Management of Growth Hormone Deficiency	208
Safety of Growth Hormone Treatment	210
Reassessment of the GH-IGF Axis at End of Growth	210
Monogenic Disorders Causing Growth Hormone Deficiency	211
Acquired GH Deficiency	211
Tumours Affecting the Hypothalamo–Pituitary Axis	211
Radiotherapy	212
Langerhans Cell Histiocytosis	213
Trauma	213
Hypophysitis	213
Disorders of GH Action and GH Sensitivity (Primary IGF-I Deficiency)	213
Bioinactive GH	213
Laron Syndrome	214
STAT5B Deficiency	214
Acid-Labile Subunit (ALS) Deficiency	214
IGF-I Gene Deletions and Bioinactive IGF-I	215
Recombinant Human IGF-I Therapy	215
Disorders of IGF-I Resistance	216
Growth Disorders not Related to the GH-IGF Axis	216
The Short Small-for-Gestational-Age Child	216
Management of Child Born SGA	217
Turner Syndrome	217
Syndromes Associated With Short Stature	219
Prader–Willi Syndrome	219
Noonan Syndrome and Associated Disorders	220
Primordial Growth Disorders	220
Silver–Russell Syndrome	220
3-M Syndrome	223
Mulibrey Nanism	223
SHORT Syndrome	223
Floating–Harbor Syndrome	223
IMAGe Syndrome	224
Bloom Syndrome	224
Microcephalic Osteodysplastic Primordial Dwarfism Type II	224
Seckel Syndrome	224
Meier–Gorlin Syndrome	224
Nijmegen Breakage Syndrome	224
Fanconi Anaemia	224
Idiopathic Short Stature	225
Treatment of ISS	226
Skeletal Dysplasias	227
Skeletal Dysplasia Classification	227
Achondroplasia	228
Hypochondroplasia	228

Leri–Weill Dyschondrosteosis and <i>SHOX</i> Deficiency	229
Tall Stature	229
Familial Tall Stature, Constitutional Tall Stature and Obesity	230
Precocious Puberty	230
GH Excess	230
Syndromes Associated with Tall Stature	231
Management of Tall Stature	232
References	233

7 Puberty and Its Disorders 235

Sasha R. Howard, Nicolas de Roux, Juliane Leger, Jean-Claude Carel, and Leo Dunkel

Normal Puberty	235
Introduction	235
Physical Changes that Occur During Puberty	236
Timing of Puberty and Relationship with Linear Growth	239
The Hypothalamic–Pituitary–Gonadal Axis	245
The Reactivation of the Gonadotropic Axis at Puberty	253
Precocious Puberty	256
Introduction	256
Aetiologies of Premature Sexual Development	256
Consequences of Precocious Puberty	259
Evaluation of the Child with Premature Sexual Development	259
Management	264
Delayed Puberty	265
Definition	265
Differential Diagnosis	265
Assessment	275
Management	278
Conclusions	283
References	284

8 The Thyroid Gland 289

Catherine Peters and Nadia Schoenmakers

Section 1: Development of the Thyroid Axis	289
Thyroid Gland Development	289
Molecular Control of Thyroid Development	290
Thyroid Hormone Biosynthesis	290
The Hypothalamic–Pituitary–Thyroid Axis	292
Negative Regulation of Thyroid Hormone Synthesis	292
Thyroid Hormone Transport	293
Thyroid Hormone Transport Proteins	293
Thyroid Hormone Metabolism	293
Thyroid Hormone Action	294
Positive Regulation of Genes by Thyroid Hormone	296
Negative Regulation of Genes by Thyroid Hormone	296
Thyroid Hormone Receptor Function	296
Thyroid Hormone Effects on Target Tissues	296
Thyroid Hormone Effects on the Gut	297
Maturation of Thyroid Hormone Development	298
Section 2: Clinical Thyroid Disorders	301
Congenital Hypothyroidism	301
Prematurity	308
Drugs/Iatrogenic	308
Fetal and Neonatal Goitre	308

Congenital Hyperthyroidism	308
TSH Receptor Mutation	309
McCune–Albright Syndrome	309
Acquired Thyroid Disorders	309
Hashimoto’s Thyroiditis	310
Graves’ Disease	311
Thyroid Storm	313
Thyrotoxic Periodic Paralysis	313
Other Forms of Thyroiditis	314
Subacute (De Quervain’s) Thyroiditis	314
Euthyroid Goitre	314
Thyroid Nodule	314
Iodine Status	314
Section 3: Diagnostic Pitfalls	315
Normal Thyroid Hormone with Elevated TSH	315
Reduced Thyroid Hormones Without TSH Elevation	315
Elevated Thyroid Hormones and Unsuppressed TSH	315
Defective TH Action – Resistance to Thyroid Hormone (RTH)	317
Defective TH Metabolism – SECISBP2	318
Defective Thyroid Hormone Transport – MCT8	319
Familial Dysalbuminaemic Hyperthyroxinaemia (FDH)	319
References	320
Weblinks	334

9 The Adrenal Cortex and Its Disorders 335

Claire R. Hughes, Elim Man, and John C. Achermann

Introduction	335
Development, Function and Regulation of the Adrenal Gland	336
History of Adrenal Medicine	336
Development and Anatomy of the Adrenal Gland	336
Steroidogenesis	339
Dynamic Regulation of Steroidogenesis	346
Steroid Hormone Actions	350
Adrenal Insufficiency (AI)	353
Overview of AI	353
Presentation of AI	355
Diagnosing AI and its Causes	358
Treatment of AI	367
Secondary AI	370
Causes of Primary AI (Excluding CAH)	372
Congenital Adrenal Hyperplasia (CAH)	381
Adrenal Excess	393
Glucocorticoid Excess (Cushing Syndrome)	393
Mineralocorticoid Excess	399
Androgen Excess	400
Education, Support and Long-Term Care	401
Education	401
Support Organizations	403
Transition and Long-Term Care	404
References	405

10 The Parathyroid and Disorders of Calcium and Bone Metabolism 409

Jeremy Allgrove and Moira Cheung

Introduction	409
--------------	-----

Physiology of Calcium and Bone Metabolism	409
Cations and Anions	409
Hormones and Other Calcitropic Agents	413
Physiology of Bone Metabolism	421
Bone Matrix	422
Bone Mineral	423
Bone Cells	423
Interactions between Calcitropic Agents	425
Fetal and Neonatal Calcium Metabolism	425
Post-Neonatal Calcium, Phosphate and Magnesium Metabolism and the Calcium Cascade	426
Investigation of Mineral Disorders	426
Clinical Conditions	426
Bone Disease of Prematurity (BDP)	426
Hypocalcaemia	428
Hypercalcaemia	446
Disorders of Bone Metabolism	454
Investigation of Bone Metabolic Disorders	454
Disorders of Bone Matrix Accompanied by Low Bone Density	455
Diseases Characterized by Increased Bone Density	459
Inherited Inflammatory Diseases of Bone	464
Disorders of Phosphate Metabolism	465
Drugs Used in the Treatment of Disorders of Calcium and Bone Metabolism	467
Vitamin D	467
Vitamin D Metabolites	467
Teriparatide (Forsteo®)	468
The Bisphosphonates	468
Denosumab	469
FGF23 Monoclonal Antibody (Burosumab [KRN23])	469
Corticosteroids	469
Loop diuretics	469
Acetazolamide	469
Calcitonin	470
Phosphate Supplements	470
Phosphate Binders	470
Cinacalcet (Mimpara®)	470
Magnesium Supplements	470
Cathepsin K Inhibitor	470
Anti-Sclerostin Antibody	470
Recombinant Human Non-Specific Alkaline Phosphatase	470
Palovarotene	470
Sodium Thiosulphate	470
Summary	470
References	472
Weblinks	479
11 Polyglandular Autoimmune Syndromes	481
<i>Catherine J. Owen, Mario Abinun, Simon H.S. Pearce, and Tim D. Cheetham</i>	
Introduction	481
Autoimmune Polyendocrinopathy Syndrome Type 1 (APS1)	483
Definition	483
Clinical Features and Course	483
Cardinal Manifestations	483

Minor Manifestations	485
Other Manifestations	486
Genetics	487
Autoantibodies and Pathogenesis	489
Diagnosis of APS1	490
Follow-up	491
Treatment	492
Prognosis	494
Summary	494
Autoimmune Polyendocrinopathy Syndrome Type 2 and Associated Disorders	494
Definitions	494
APS2	494
APS3	496
Genetics	496
Autoantibodies and Pathogenesis	497
Diagnosis and Follow-up	498
Management	498
Prognosis	499
Summary	499
Other Single Gene Disorders Associated with Immune Dysregulation and Autoimmune Endocrinopathies	499
Conclusion	502
References	502

12 Endocrine Neoplasia 507

<i>Constantine A. Stratakis and Emmanouil Saloustros</i>	
Thyroid Neoplasia: Nodules and Cancer	507
Epidemiology	507
Pathogenesis	508
Clinical Presentation and Diagnostic Evaluation	508
Management	509
Parangliomas and Pheochromocytomas	511
Epidemiology	511
Pathology	511
Pathogenesis	511
Genetic Syndromes Associated with PHEOs/PGLs	512
Clinical Presentation	516
Diagnosis	516
Treatment	518
Adrenocortical Cancers	521
Epidemiology	521
Pathogenesis	521
Clinical Presentation	522
Diagnosis	523
Treatment	523
Tumours of the Ovary	524
Ovarian Germ Cell Tumours (GCTs)	524
Ovarian Sex Cord Stromal Tumours (SCSTs)	525
Tumours of the Testes	528
Testicular Germ Cell Tumours (GCTs)	528
Testicular Stromal Cell Tumours (SCTs)	529
References	530

- 13 Endocrine Late Effects of Cancer Treatments 533**
Wassim Chemaitilly and Melissa M. Hudson
 Prevalence and Risk Factors for Endocrine Late Effects 538
 Survivors of Childhood Central Nervous System (CNS) Tumours 538
 Survivors Treated with Haematopoietic Stem Cell Transplantation (HSCT) for Haematological Malignancies 541
 Endocrine Late Effects in Survivors of Non-HSCT Requiring Childhood Leukaemia 543
 Endocrine Late Effects in Survivors of Childhood Hodgkin's Lymphoma (HL) 544
 Endocrine Late Effects in Survivors of Childhood Malignant Extra-Cranial Solid Tumours 545
 Diagnosis and Management of Common Endocrine Late Effects 546
 Disorders of the Hypothalamo–Pituitary Axis 546
 Disorders of the Thyroid 547
 Disorders of the Gonads 548
 Bone Mineral Density Deficit 548
 Overweight, Obesity and Glucose Intolerance 548
 Preparing for the Transition to the Adult Care Setting 549
 Endocrine Complications and Novel Cancer Therapies 549
 Summary 550
 References 550
 Weblinks 552
- 14 Disorders of Water Balance 553**
Natascia Di Iorgi, Flavia Napoli, Giovanni Morana, and Mohamad Maghnie
 Regulation of Water Balance 554
 Anatomy of the Hypothalamic–Posterior Pituitary Axis 554
 Neurons, Periphery and Regulation of Thirst 554
 Vasopressin Biosynthesis 555
 Physiology of Water Homeostasis 556
 Regulation of Vasopressin Secretion 557
 Diabetes Insipidus (DI) 558
 Definition of DI 558
 Epidemiology 558
 Central Diabetes Insipidus 559
 Genetic Forms of Central Diabetes Insipidus 559
 Acquired Forms of Idiopathic Central Diabetes Insipidus (CDI) 561
 Diagnosis of Central Diabetes Insipidus 564
 Imaging Findings in CDI 566
 Follow-up and Long-Term Outcomes 571
 Central Diabetes Insipidus and Adipsia 572
 Primary Polydipsia 572
 Nephrogenic Diabetes Insipidus 573
 The Syndrome of Inappropriate Antidiuretic Hormone Secretion 573
 Management of Central Diabetes Insipidus 573
 Treatment of Nephrogenic Diabetes Insipidus 574
 Treatment of Inappropriate Antidiuretic Hormone Secretion 574
 Challenges 575
 Conclusions 575
 Clinical Guidelines 575
 References 576
- 15 Diabetes Mellitus 583**
G.R. Ambler, F.J. Cameron, K. Joshi, and D.K. Wherrett
 Type 1 Diabetes 583
 Epidemiology 583

Pathophysiology	585
Preventive Interventions	590
Diagnosis	593
Management and Therapies	594
Acute Complications	615
Chronic Complications	622
Prognosis	625
Type 2 Diabetes	626
Epidemiology	626
Pathophysiology	626
Preventive Interventions	632
Diagnosis	632
Management and Therapies	633
Acute Complications	636
Chronic Complications	636
Prognosis	637
Cystic Fibrosis-Related Diabetes	637
Incidence	638
Diagnosis	638
Management and Therapies	638
Prognosis	639
Other Dysglycaemia in Cystic Fibrosis	639
Monogenic Forms of Diabetes	639
Maturity Onset Diabetes of The Young (MODY)	639
Neonatal Diabetes Mellitus (NDM)	642
Transient Neonatal Diabetes Mellitus (TNDM)	643
Permanent Neonatal Diabetes Mellitus (PNDM)	643
Syndromic Neonatal Diabetes Mellitus	645
Diagnosis	645
Treatment	646
Rare Forms of Diabetes	647
Defects in Insulin Secretion	647
Living with Diabetes	648
Education	648
Employment	648
Driving	649
References	649

16 Disorders Associated with Hypoglycaemia in Children 671

<i>Pratik Shah, Emma Footit, and Ritika Kapoor</i>	
Introduction	671
Physiology of Blood Glucose Control	672
Glucose Production	672
Renal Contribution to Glucose Homeostasis	672
Glucose Utilization	672
Role of Gut Hormones in Glucose Homeostasis	673
Metabolic Adaptation to Birth	673
Metabolic Adaptation to Feeding and Fasting	674
The Regulation of Insulin Secretion and Role of K_{ATP} Channels	675
Glucose-Stimulated Insulin Secretion (GSIS)	675
Definition of Hypoglycaemia	676
Screening	677
Numerical Cut-Offs Used in Clinical Practice	677
Aetiology and Clinical Approach to Hypoglycaemia	678

Age of Onset	678
Past History	678
Pregnancy, Birth and Neonatal History	679
Family History	680
Dietary and Drug History	680
Examination	680
Investigations for Hypoglycaemia	680
Urgent Investigations	680
Fast Provocation Test	680
Other Planned Investigations	681
Emergency Management of Hypoglycaemia	682
Causes of Hypoglycaemia	682
Hyperinsulinaemic Hypoglycaemia	682
Hypoketotic Hypoinsulinaemic Hypoglycaemia	687
Factitious Hypoglycaemia	687
Failure of Counter-Regulatory Hormones	688
Inborn Errors of Metabolism Presenting with Hypoglycaemia	689
References	693
17 Obesity	701
<i>Wieland Kiess</i>	
Introduction	701
Definitions, Differential Diagnosis, Assessments and Measurements	701
Aetiology of Obesity	703
Common or Multifactorial Obesity and Fetal Programming	705
Neurobiology of Satiety and Hunger	705
Hedonistic Signals and Addiction	706
Behaviour, Hypothalamus and Obesogenic Environment	707
Biology of Adipose Tissue and Adipocytes	707
Microbiota	708
Endocrinology of Obesity	709
Epigenetics	709
Social Inheritance	709
Sociodemographics	710
Nutrition and Malnutrition	710
Physical Activity	711
Sedentary Behaviour	711
Endocrine-Disrupting Chemicals and Toxicology	711
Media Use	712
Cultural Aspects	712
Evolution	712
Epidemiology	713
Developed Countries	713
Developing Countries	713
Co-Morbidities and Consequences	713
Carbohydrate Metabolism	714
Lipid Metabolism	715
Cardiovascular	715
Skeletal System	715
Non-Alcoholic Fatty Liver Disease (NAFLD, NASH)	716
Metabolic Syndrome	716
Urogenital	717
Puberty and Fertility	717
Psychology and Psychiatric Co-Morbidity	718

Social Participation	718
Mortality	719
Health Economics	720
Treatments	720
Medical Management	720
Multidisciplinary Therapeutic Approach	720
Nutrition Treatment and Dieting	721
Physical Activity Training	721
Behavioural Therapies	721
Family-Based Therapies and Community-Based Therapies	721
Bariatric Surgery	721
Pharmacotherapy	722
Prevention	722
Community and Society	723
Microbiota	723
Urban Living	724
Advertising Industries	724
Conclusions	725
Further Reading	726
Weblinks	728

18 Genetic Obesity Syndromes 729

Tinh-Hai Collet and I. Sadaf Farooqi

Introduction	729
Genetic Contributors to Obesity: The Evidence	729
Genetic Obesity Syndromes: An Overview	730
Obesity with Developmental Delay	730
Prader–Willi Syndrome	730
Albright’s Hereditary Osteodystrophy	731
Bardet–Biedl Syndrome	731
BDNF and TrkB Deficiency	731
SIM1 Deficiency	731
Obesity Without Development Delay	732
Leptin and Leptin Receptor Deficiency	732
Disorders Affecting Pro-Opiomelanocortin (POMC) and POMC Processing	733
PC1/3 (PCSK1) Deficiency	733
MC4R Deficiency	733
SH2B1 Deficiency	734
KSR2 deficiency	734
Conclusions	734
References	734
Weblinks	736

19 Endocrine Care During Adolescence into Young Adulthood 737

Helena Gleeson

Introduction	737
Adolescence and Young Adulthood	737
Biopsychosocial Development and Growing Up with an Endocrine Condition	737
Exploratory and Health-Related Behaviours	740
Developmentally Appropriate Healthcare	740
Designing Services to Meet Young People’s Needs	740
Training Healthcare Providers	741
Clinic Consultations	741
Addressing Adherence	743

Involving Parents	743
Transition and Transfer to Adult Services	744
Evidence Base for Transition and Transfer	744
Monitoring Transition and Transfer	744
Young People with Endocrine Conditions	744
Endocrine Care in Adolescence	746
Symptoms and Signs of PCOS in Adolescence	746
Conclusion	750
References	751
Index	757

List of Contributors

Mario Abinun

Honorary Clinical Senior Lecturer
Newcastle University; and
Department of Paediatric Immunology
Royal Victoria Infirmary
Newcastle upon Tyne
UK

John C. Achermann

Genetics & Genomic Medicine Programme
UCL Great Ormond Street Institute of Child Health
London, UK

Kyriaki-Sandy Alatzoglou

Consultant in Paediatrics & Endocrinology, Chelsea
& Westminster Hospital NHS Foundation Trust
London, UK

Jeremy Allgrove

Consultant Paediatric Endocrinologist,
Department of Paediatric Endocrinology,
Great Ormond Street Hospital for Children
Foundation Trust, London, UK

G.R. Ambler

Institute of Endocrinology and Diabetes, The
Children's Hospital at Westmead and Clinical School
The University of Sydney, Sydney, Australia

Anu Bashamboo

Human Developmental Genetics, Institut Pasteur
Paris, France

Gerhard Binder

University Children's Hospital, Pediatric Endocrinology
and Diabetology, Tübingen, Germany

F.J. Cameron

Department of Endocrinology and Diabetes
Royal Children's Hospital, Parkville, Victoria
Australia

Jean-Claude Carel

Assistance Publique-Hôpitaux de Paris, Robert
Debré University Hospital, Paediatric Endocrinology
Diabetology Department, Reference Center for Growth
and Development Endocrine Diseases
Paris Diderot University, INSERM U1141
Paris, France

P.E. Clayton

Division of Developmental Biology and Medicine
School of Medical Sciences, Faculty of Biology
Medicine and Health, University of Manchester;
and
Department of Paediatric Endocrinology
Royal Manchester Children's Hospital
Manchester, UK

Tim D. Cheetham

University Reader and Honorary Consultant in
Paediatric Endocrinology, Newcastle University;
and
Department of Paediatric Endocrinology
Royal Victoria Infirmary, Newcastle upon Tyne, UK

Wassim Chemaitilly

Department of Pediatric Medicine-Division of
Endocrinology, St. Jude Children's Research Hospital;
and
Department of Epidemiology and Cancer Control
St. Jude Children's Research Hospital
Memphis, TN, USA

Moira Cheung

Consultant Paediatric Endocrinologist, Evelina
Children's Hospital, Guy's and St Thomas' Hospital
NHS Foundation Trust, London, UK

Tinh-Hai Collet

University of Cambridge Metabolic Research
Laboratories, Wellcome Trust-MRC Institute of
Metabolic Science, Addenbrooke's Hospital
Cambridge, UK

Martine Cools

Ghent University Hospital – Princess Elizabeth Children’s Hospital, Ghent University, Ghent, Belgium

Mehul T. Dattani

Professor and Head of Paediatric Endocrinology Genetics and Genomic Medicine Programme UCL Great Ormond Street Institute of Child Health Great Ormond Street Hospital for Children NHS Foundation Trust London, UK

Leo Dunkel

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London London, UK

I. Sadaf Farooqi

University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital Cambridge, UK

Emma Footit

Department of Metabolic Medicine Great Ormond Street Children’s Hospital London, UK

Hoong-Wei Gan

Clinical Research Fellow & Paediatric Endocrinology Registrar, Genetics & Genomic Medicine Programme UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

Evelien F. Gevers

Department of Pediatric Endocrinology, Royal London Children’s Hospital, Barts Health NHS Trust; and Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London London, UK

Helena Gleeson

Consultant Endocrinologist University of Birmingham Hospitals Birmingham, UK

Sasha R. Howard

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London London, UK

Melissa M. Hudson

Department of Epidemiology and Cancer Control St. Jude Children’s Research Hospital; and Department of Oncology, Division of Cancer Survivorship, St. Jude Children’s Research Hospital Memphis, TN, USA

Claire R. Hughes

Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London & Royal London Children’s Hospital, Barts Health NHS Trust London, UK

Natascia Di Iorgi

Department of Pediatrics, Istituto Giannina Gaslini University of Genova, Genova, Italy

K. Joshi

Department of Endocrinology and Diabetes, Royal Children’s Hospital, Parkville, Victoria, Australia

Ritika Kapoor

Department of Paediatric Endocrinology, Kings College Hospital London, London, UK

Harshini Katugampola

Great Ormond Street Hospital for Children NHS Foundation Trust; and Genetics & Genomic Medicine Programme, UCL GOS Institute of Child Health, London, UK

Wieland Kiess

Hospital for Children and Adolescents, Centre of Paediatric Research, Department of Women & Child Health, University of Leipzig, Leipzig, Germany

Birgit Köhler[†]

Department of Paediatric Endocrinology and Diabetology, Charité, Universitätsmedizin Berlin Germany

Juliane Leger

Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paediatric Endocrinology Diabetology Department, Reference Center for Growth and Development Endocrine Diseases, Paris Diderot University, INSERM U1141 Paris, France

Mohamad Maghnie

Department of Pediatrics, Istituto Giannina Gaslini University of Genova, Genova, Italy

[†] Deceased

Elim Man

Paediatric Endocrinology, Queen Mary Hospital, The University of Hong Kong, HKSAR, Hong Kong; and Genetics & Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health London, UK

Ken McElreavey

Human Developmental Genetics, Institut Pasteur Paris, France

Giovanni Morana

Department of Pediatric Neuroradiology, Istituto Giannina Gaslini, Genova, Italy

P.G. Murray

Division of Developmental Biology and Medicine School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester; and Department of Paediatric Endocrinology Royal Manchester Children's Hospital Manchester, UK

Flavia Napoli

Departments of Pediatrics, Istituto Giannina Gaslini Genova, Italy

Catherine J. Owen

Consultant in Paediatric Endocrinology Department of Paediatric Endocrinology Royal Victoria Infirmary Newcastle upon Tyne UK

Simon H.S. Pearce

Professor of Endocrinology Institute of Genetic Medicine Newcastle University Newcastle upon Tyne UK

Catherine Peters

Consultant Paediatric Endocrinologist, Great Ormond Street Hospital, London, UK

Nicolas de Roux

Biochemistry Laboratory, INSERM U1141, Robert Debré Hospital, Paris Diderot University Paris, France

Emmanouil Saloustros

Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA

Nadia Schoenmakers

Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge Cambridge, UK

Pratik Shah

Department of Paediatric Endocrinology, Great Ormond Street Children's Hospital, London, UK

Constantine A. Stratakis

Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA

D.K. Wherrett

Division of Endocrinology, Department of Paediatrics Hospital for Sick Children, University of Toronto Toronto, ON, Canada

Preface

It is nearly 40 years since I wrote the preface to the first edition of this book. There have not been fundamental changes in the clinical practice of pediatric endocrinology during those years but the era of molecular biology has changed completely the understanding of the causation of many of the disorders seen and described in this edition of the book. In years to come it will impinge on clinical practice.

Major changes have occurred in the access to information through the internet and also in the ways that a book is now assembled, prepared and printed in different parts of the world. The ready access to original literature seemed likely to make text books like this redundant but the plethora and complexity of the information available makes even more relevant the authoritative digestion of data and their presentation in a clinically useful format. This has always been the aim of the book.

One loss with the internet is the close personal relationships which used to exist between editors, authors and their publisher; so many people are now involved in the actual production of a book that it is no longer possible to identify exactly who does what. Nevertheless I thank our authors and all at Wiley for their endeavours.

Although I have claimed the right to be the sole author of the preface for this edition of *Clinical Pediatric Endocrinology* (which will be the last in which I shall be involved), it will be clear that the brains behind the book are those of my long-term colleague, now mentor and friend, Mehul T. Dattani. His time in many roles in what was my department and is now his spans 30 years. I and many others respect and admire his achievements and this edition would never have seen the light of day without him. My contribution has been trying to make the book readable, which is not always an easy task.

The number of practitioners of clinical pediatric endocrinology worldwide has increased by at least two orders of magnitude since 1981 and so no longer is this edition dedicated to just the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society but to all who strive to advance our field. Lastly, I should acknowledge with love and gratitude the way my wife Catherine has put up with this cuckoo in our nest for so many years.

*Charles G. D. Brook
Hadspen Farm, Somerset, UK*

Acknowledgement

I would also like to thank my children Seyan Dattani and Arushi Dattani for their help in checking the proofs.

About the Companion Website

This book is accompanied by a companion website:

www.wiley.com/go/dattani/brookcpe7

The website includes:

MCQs



1

Genetics and Genomics

Anu Bashamboo and Ken McElreavey

Human Developmental Genetics, Institut Pasteur, Paris, France

Introduction

The Human Genome Project was completed in 2003 but it is only now that we are truly in the genomic era. Next-generation sequencing (NGS), which allows genome-wide detection of variants, is transforming on an unprecedented scale our understanding of pediatric and endocrine diseases by identifying mutations that are pathogenic or confer disease risk: new genes that cause human disease are being identified at the rate of 3 per week. We all differ in our DNA sequence and medical geneticists aim to understand the significance of this genetic diversity in health and disease, which has led to the age of genomic medicine.

Understanding genetic diversity is essential to understanding the biology of diseases of various kinds, from simple *Mendelian or monogenic disorders* to more complex *multifactorial disease*, and how we respond to treatment at both population and individual levels. We have the capacity to study the human genome as an entity rather than one gene at a time and medical and clinical genetics has become part of the broader field of genomic or *precision medicine*, which seeks to apply a large-scale analysis of the human genome to provide an individual and knowledge-based approach to medical care.

Many web resources and web-based tools have been developed to help the clinicians navigate and interpret the tremendous amount of genomic data that are being generated (Table 1.1).

The term ‘-omics’ aims at the collective characterization and quantification of pools of biological molecules that translate into the structure, function and dynamics of an organism. Genomics can be divided into *comparative genomics*, the study of the relationship of genome structure and function across different biological species or strains; *functional genomics*, which describes gene and protein functions and interactions; *metagenomics*, the

study of genetic material recovered directly from environmental samples; and *epigenomics*, which is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome.

Basic Concepts in Human Genetics and Genomics

Genes and Chromosomes

Genetic information is stored in DNA in the chromosomes within the cell nucleus. DNA is a polymeric nucleic acid macromolecule composed of a five-carbon sugar (deoxyribose), a nitrogen-containing base and a phosphate group. The bases are of two types, purines and pyrimidines. In DNA, there are two purine bases, adenine (A) and guanine (G), and two pyrimidine bases, thymine (T) and cytosine (C). DNA is organized in a helical structure in which two polynucleotide chains run in opposite directions, held together by hydrogen bonds between pairs of bases, A of one chain pairing with T of the other and G with C. In the coding sequences of a gene, each set of three bases constitutes a *codon* that encodes for a particular amino acid. *Genome* refers to the totality of genetic information carried by a cell or an organism, whereas *genotype* is the genetic constitution of an individual cell or organism. With the exception of cells that develop into gametes (the germline), all cells that contribute to the body are termed somatic cells.

The human genome contained in the nucleus of the somatic cells consists of 46 chromosomes arranged in 23 pairs, 22 of which are common in both males and females and are termed autosomes, and the remaining pair being the sex chromosomes, two X chromosomes in females and an X and a Y chromosome in males. *Homologous chromosomes* refer to members of a pair of chromosomes which carry the same genes in a similar organization.

Table 1.1 Commonly used databases in human genetic and genomic analysis.

Site	Content	URL
National Center for Biotechnology Information	A portal that provides access to a wealth of biomedical and genomic information. Includes PubMed, OMIM, dbSNP, Clinvar, expression data sets. Suite of tools for data and sequence analysis (e.g. BLAST)	http://www.ncbi.nlm.nih.gov
Mendelian Inheritance in Man (MIM)	A comprehensive database of human genes and genetic disorders	http://www.ncbi.nlm.nih.gov/omim
ClinGen	Authoritative central resource that defines the clinical relevance of genes and variants for use in precision medicine and research	https://www.clinicalgenome.org
Ensembl	Genome browser for vertebrate genomes that supports research in comparative genomics, evolution, sequence variation and transcriptional regulation. Annotates genes, computes multiple alignments, predicts regulatory function and collects disease data	http://www.ensembl.org
University California, Santa Cruz (UCSC), genome browser	Genome browser offering access to genome sequence data from vertebrate and invertebrate species and major model organisms. Integrated with a large collection of analysis tools	https://genome.ucsc.edu
GeneCards	Provides comprehensive information on all human genes. It integrates gene data from ~125 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information	http://www.genecards.org
Human Gene Mutation Database (HGMD)	Collates published gene lesions responsible for human inherited disease	www.hgmd.cf.ac.uk/ac
Mouse Genome Informatics at the Jackson Laboratories	International database resource for the laboratory mouse, providing integrated genetic, genomic, and biological data to facilitate the study of human health and disease	http://www.informatics.jax.org
DECIPHER database	Collects clinical information about rare genomic variants and displays this information on the human genome map	https://decipher.sanger.ac.uk
Database of Genomic Variants (DGV)	A curated catalogue of human genomic structural variation	http://dgv.tcag.ca/dgv/app/home
Exome Aggregation Consortium (ExAC) browser	Exome data set >60,000 unrelated individuals. Provides both a reference set of allele frequencies and constraint metrics giving information on whether a gene is tolerant or intolerant to variation	http://exac.broadinstitute.org
ClinVar	Aggregates information about genomic variation and its relationship to human health.	http://www.ncbi.nlm.nih.gov/clinvar
Sequence Variant Nomenclature	Provides guidelines for sequence variation nomenclature	http://varnomen.hgvs.org
dbSNP	Genetic variation within and across different species. Not limited to SNPs, it contains a range of molecular variation	http://www.ncbi.nlm.nih.gov/SNP
F-SNP	Provides integrated information about the functional effects of SNPs obtained from 16 bioinformatics tools and databases. Helps identify and focus on SNPs with potential pathological effect to human health	http://compbio.cs.queensu.ca/F-SNP
Biological General Repository for Interaction Datasets (BioGRID)	Database of protein–protein interactions, genetic interactions, chemical interactions, and post-translational modifications	http://thebiogrid.org

Table 1.1 (Continued)

Site	Content	URL
PhenomicDB	A multi-organism phenotype–genotype database including human, mouse, fruit fly, <i>C. elegans</i> , and other model organisms	http://www.phenomicdb.de
Phencode	Connects human phenotype and clinical data in various locus-specific mutation databases with data on genome sequences, evolutionary history and function in the UCSC Genome Browser	http://phencode.bx.psu.edu
Human Epigenome Atlas	Includes human reference epigenomes and the results of their integrative and comparative analyses. Provides details of locus-specific epigenomic states like histone marks and DNA methylation across tissues and cell types, developmental stages, physiological conditions, genotypes and disease states	http://www.genboree.org/epigenomeatlas
Encyclopedia of DNA Elements (ENCODE)	Catalogue of functional elements in the human genome, including elements that act at the protein and RNA levels and regulatory elements that control cells and circumstances in which a gene is active	https://www.encodeproject.org
Genomics England 100,000 Genomes Project	The project will sequence 100,000 genomes from around 70,000 people. Participants are National Health Service (UK) patients with a rare disease, plus their families, and patients with cancer	www.genomicsengland.co.uk/the-100000-genomes-project




Figure 1.1 Example of a typical mammalian gene structure. A typical gene has regulatory regions preceding the coding exons interspersed by non-coding introns. The individual labelled features are discussed in detail in the text.

A *gene* is a sequence of DNA in the genome required for the expression of a functional product, including a polypeptide or RNA molecule (Figure 1.1). The majority of human genes are organized as coding regions called *exons* interrupted by one or more non-coding regions termed *introns*. Introns are initially transcribed into RNA in the nucleus but are not present in mature mRNA, which also has flanking 5' and 3' *untranslated regions* (UTRs). The latter contains a signal for the addition of adenosine residues (the polyA tail) to the end of the mature mRNA.

Other sequences within the 3' UTR are important for translation efficiency, localization and stability, whereas

the 5' UTR is important in the regulation of RNA translation. It is important when discussing genes to define what is meant by the terms *trans* and *cis*. *trans*-Acting usually means 'acting from a different molecule', whereas *cis*-acting means 'acting from the same molecule'. In genetics and genomics, *cis*-acting elements refer to DNA sequences in the vicinity of a gene that are required for gene expression; *trans*-acting factors, either proteins or some classes of RNA molecules, bind to the *cis*-acting sequences to control gene expression.

Many genes produce not just one but multiple proteins, which is achieved either by *alternative splicing* of the coding segments of genes or by numerous types of

biochemical modifications of the resulting proteins so that the 19,000 genes in the human genome are estimated to generate over a million different proteins. The other point to remember is that individual proteins rarely work by themselves. The cell is composed of modular supramolecular complexes and each complex performs an independent, discrete biological function that could not be achieved by the independent components of the complex. The transfer of information from the DNA strand to the protein is mediated by RNA, which directs the synthesis and sequence of polypeptides.

Genetic information is stored in genes in the form of a genetic code in which the sequence of adjacent bases determines the sequence of amino acids in the polypeptide. RNA is synthesized from DNA by *transcription* and the RNA carrying the coded information is termed *messenger RNA* (mRNA), which is transported from the nucleus to the cytoplasm where it is translated to synthesize the protein. This constitutes the central dogma of molecular biology.

Regulation of Gene Expression

Gene expression is the production of correct RNA, which is a complex process where the RNA must be expressed in the appropriate cell type in the correct amount and, in some cases, at a precise developmental time. Nucleic acid sequences flanking the coding sequences and in some cases within the coding sequences provide the molecular signals for gene transcription. A *promoter* region that contains sequences necessary for the initiation of transcription lies at the 5' end of most genes. An *enhancer* is a short (50–1500 bp) region of DNA that can be bound by proteins (transcription factors) to increase the likelihood that transcription of a particular gene will occur. Enhancers are generally located up to 1 Mbp away from the gene and can be upstream or downstream of the gene it regulates. The orientation of an enhancer may even be inverted without having an effect on its function.

Genes that are necessary for complex and multiple developmental processes usually have a number of enhancers with overlapping functions. A good example is the *SOX9* locus: the developmental timing and tissue-specific transcriptional regulation of *SOX9* are highly complex and involve multiple elements located in flanking regions of at least 1 Mb upstream and 1.6 Mb downstream and these show strikingly different phenotypes when mutated. Upstream rearrangements are associated with campomelic dysplasia and fall within two clusters located about 400 kb apart. Large (>1 Mb) duplications 5' to *SOX9* (i.e. downstream) are associated with brachydactyly anonychia (symmetric brachydactyly of the

hands/feet, hyponychia or anonychia). Pierre Robin sequence (micrognathia, cleft palate and macroglossia) is caused by either a deletion located 1.38 Mb upstream or a deletion located 1.56 Mb downstream of *SOX9*.

Another regulatory element, termed *RevSex*, is located 600 kb upstream of *SOX9* gene. Three copies of *RevSex* are associated with testicular or ovotesticular disorders of sex development (DSD), whereas deletions (one copy) of *RevSex* are associated with 46,XY gonadal dysgenesis.

RNA Editing

RNA editing is a molecular process through which cells can make discrete changes to specific nucleotide sequences within a RNA molecule. RNA editing includes nucleotide additions and insertions as well as nucleobase modifications such as cytidine (C) to uridine (U) and adenosine (A) to inosine (I), which is termed deamination. RNA editing in mRNAs alters the amino acid sequence of the encoded protein so that it differs from that predicted by the genomic DNA sequence.

Various post-translational modifications after protein biosynthesis can extend the chemical repertoire of the 20 amino acids by introducing new functional groups such as phosphate, acetate, amide groups or methyl groups. This can occur on the amino acid side chains or at the protein's carboxy (C-) or amino (N-) termini. The most common post-translational modifications in descending order are phosphorylation, acetylation, N-linked glycosylation, palmitoylation and O-linked glycosylation.

Classes of RNA Molecules and their Functions

In recent years there has been a substantial shift in understanding the importance of different classes of RNA molecules in biological processes. Ninety percent of the human genome is transcribed, but many of the resulting transcripts and the factors regulating their transcription remain uncharacterized. The vast majority of the transcribed genome comprises diverse classes of *non-coding RNAs* (ncRNAs) that may play key roles in different biochemical and cellular processes with profound implications for human health and disease. The cellular repertoire of ncRNAs consists of small house-keeping RNAs, such as *ribosomal RNAs* (rRNAs) and *transfer RNAs*, *microRNAs*, and *long ncRNAs* (lncRNAs). Assigning molecular, cellular, and physiological functions to well-annotated ncRNAs is the current challenge in this field. ncRNAs are emerging as key players in pediatric and endocrine diseases.

MicroRNAs, Small Interfering RNAs, and Piwi-interacting RNAs

Small RNAs usually refers to any class of non-coding RNA of 19–32 nt (Table 1.2). The role of small RNAs is continuing to be explored but their main function is *gene silencing* through RNA-mediated mechanisms. *RNA silencing* is an umbrella term for all small RNA-mediated inhibition of transcription, translation and deactivation of transposable elements. RNA silencing is widely regarded as a master controller of gene regulation but small RNAs have important roles in an increasing variety of eukaryotic biological processes. For example, small RNAs may play a role in transgenerational inheritance and epigenetic memory.

In eukaryotes, there are three major classes of small RNAs involved in post-transcriptional regulation: microRNAs (miRNAs), small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNA). All find target RNAs by base pairing between complementary sequences, causing target RNA degradation and/or translational repression. Each type has its own preferred class of RNA targets, reflecting their biological functions. miRNAs and siRNAs bind to proteins in the Argonaute subfamily, whereas piRNAs bind to the Piwi subfamily of proteins.

MicroRNAs (miRNAs) are an abundant class of small evolutionarily conserved regulatory RNAs about 19–22 nucleotides (nt) in length. They are thought to play fundamental roles in most biological processes including disease. Over 1500 miRNAs have been identified that regulate the expression of up to 60% of mammalian genes. The canonical miRNA pathway starts with the

transcription of miRNA genes by RNA polymerase II, which results in the production of the primary miRNA (pri-miRNA). The pri-miRNA transcript is cleaved by a protein complex consisting of Drosha/DGCR8 to generate an ~80 base-pair precursor miRNA (pre-miRNA) with a characteristic hairpin secondary structure vital for enabling export from the nucleus.

Dicer, an RNase III/helicase multi-domain enzyme, processes the pre-miRNA into a ~22 bp miRNA. The gene encoding DICER is termed *DICER1*. *DICER1* syndrome is an inherited disorder that increases the risk of a variety of cancerous and benign tumours, including pleuropulmonary blastoma, cystic nephroma, multinodular goiter and Sertoli–Leydig cell tumours of the ovary, which typically develop in affected women in their teens or twenties. Some Sertoli–Leydig cell tumours release testosterone resulting in virilization.

Incorporated into one member of the Argonaute (Ago) protein family is the RNA-induced silencing complex (RISC), a mature miRNA that binds typically to the 3'-UTR of the mRNA and inhibits its translation via various mechanisms including mRNA degradation. The key determinant of target recognition is a short sequence complementarity between the miRNA seed sequence (the second–eighth nucleotides of the miRNA) and the target mRNA. The maturation and function of miRNAs are highly dependent on the coordinated action of several RNA-binding proteins.

The miRNA genes are mainly clustered in the genome and are transcribed as *polycistronic* primary transcripts. Forty percent of miRNA genes lie in the introns of protein and non-protein coding genes. These are usually,

Table 1.2 Characteristics of the three major classes of small RNAs involved in post-transcriptional regulation.

Properties	miRNA	piRNA	siRNA
Size (nt)	20–24 (usually 22)	26–31	20–25
Origin	Endogenous and ubiquitous	Endogenous to germ cell lineages	Exogenous or endogenous
Evolutionary conservation	Eukaryotes	Vertebrates and invertebrates	Eukaryotes
Precursor	Single-stranded RNA	Single-stranded RNA	Double-stranded RNA
Biogenesis	Dicer dependent	Dicer independent	Dicer dependent
Base-pair match to target	Imperfect	Perfect	Perfect
Distribution	Cytoplasmic and nuclear	Cytoplasmic and nuclear	Cytoplasmic
Ago dependence	Ago subfamily	Piwi subfamily	Ago subfamily
Target nucleic acid	3'UTR, 5'-UTR, promoters, coding regions, pseudogenes	Transposons	mRNA, promoters
Main functions	Translation inhibition, mRNA degradation, transcriptional and post-transcriptional silencing	Transposon silencing, transcriptional and post-transcriptional silencing	mRNA degradation, transcriptional and post-transcriptional silencing

though not exclusively, found in a sense orientation and thus are regulated together with their host genes. Pre-miRNAs that are spliced directly out of introns are termed *Mirtrons*. Approximately 16% of pre-miRNAs are modified by nuclear RNA editing, leading to changes in biological function. This is mainly mediated by adenosine deaminases acting on RNA to catalyse adenosine to inosine (A to I) transitions. RNA editing can result in disruption of nuclear processing as well as alter downstream processes including cytoplasmic miRNA processing and target specificity.

Gene regulation by miRNAs is of key importance in many fundamental biological processes such as cellular differentiation, proliferation, migration and apoptosis. In disease, some circulating blood miRNA levels are proportional to the degree of severity of the pathology, such as drug-induced liver injury, cardiovascular infection, cancer, Alzheimer's disease, inflammation and metabolic diseases (obesity). Altered expression of miRNAs in diabetes causes malfunction of insulin release and insulin resistance. The use of miRNAs as biomarkers for type 1 diabetes (T1D) risk is attractive as these markers could be used to identify individuals at risk for developing T1D before symptoms appear. Twelve miRNAs were found to be more concentrated in sera from children and adolescents with newly diagnosed T1D compared with sera from age-matched controls. Among them, miR-25 was associated with improved glycaemic control and better residual β -cell function, suggesting that this miRNA could be used during early and intensive management of newly diagnosed diabetes to improve blood glucose control and reduce microvascular complications.

piRNA is the largest class of small non-coding RNA molecules expressed in animal cells. piRNAs are generated from various portions of long single-stranded precursor RNAs transcribed from genomic loci termed piRNA clusters, which are often >100 kb in size. They are distinguished from miRNA by their size (26–31 nt), lack of sequence conservation and increased sequence complexity. The majority are antisense to transposon sequences, indicating that transposons are the piRNA target. piRNAs direct the Piwi proteins to their transposon targets for gene silencing. The piRNA-mediated repression of transposons is best characterized in the germline. piRNAs are necessary for spermatogenesis in humans.

siRNAs are derived from long double-stranded precursor RNAs (dsRNAs). Endogenously formed dsRNAs are exported to the cytoplasm where they are cleaved into 20–25-nt duplexes by Dicer. One strand of these fragments, usually the antisense strand, is incorporated into multiprotein RISCs composed of one of a family of Argonaute proteins together with auxiliary proteins that extend or modify the function. In contrast to miRNAs,

siRNAs have a sequence fully complementary to their target mRNA and usually have a single target mRNA. Depending on the source of dsRNA precursor, siRNAs can be further divided into exogenous and endogenous siRNAs (exo- and endo-siRNAs, respectively).

LncRNAs

LncRNAs, non-protein-coding RNA transcripts longer than 200 nucleotides (nt), are emerging as key regulators of diverse cellular processes. The definition of lncRNAs continues to evolve. The first reported example of a long non-coding RNA (lncRNA) was the *H19* transcript, which lacked large open reading frames and was not translated into protein. Later work revealed the existence of thousands of lncRNAs in the human genome. The expression of lncRNAs is usually low but they are transcribed in a highly regulated manner, either from their own promoter sequence or as a by-product of other transcriptional processes. Although some lncRNAs are located within intergenic sequences, the majority are transcribed as complex, interlaced networks of overlapping sense and antisense transcripts that often include protein-coding genes. They are generally, but not exclusively, spliced, 5'-capped and 3'-polyadenylated, and transcribed by RNA polymerase II.

Approximately one-third to one-half of lncRNAs overlap protein-coding genes. Genic lncRNAs can be further divided into those that overlap protein-coding loci in the sense or antisense direction and those that overlap exonic or intronic regions of the protein-coding gene. A universal classification does not exist. The 200-nt cut-off to define their size is arbitrary and does not represent a biological distinction. A lncRNA may code for a polypeptide but it must have coding-independent functions, as shown for the steroid receptor RNA activator (SRA), a well-characterized bifunctional lncRNA involved in the nuclear receptor-mediated regulation of gene expression. The SRA1 gene expresses both SRA RNA and the SRA protein (SRAP). This gene is involved in the regulation of many NR and non-NR activities, including metabolism, adipogenesis and chromatin organization. The encoded protein, SRAP, acts as a transcriptional repressor by binding to the non-coding RNA. SRA coactivates a range of nuclear receptors including ER α and ER β in a ligand-dependent manner by direct interaction with other co-regulatory proteins. lncRNAs are becoming increasingly important in oncology. The dysregulation of lncRNAs expression is highly specific to the cancer type as compared to the protein-coding genes. lncRNAs are being identified as drivers of cancer with their potential functions being predicted. This is providing a framework for the development of new cancer diagnostics, stratification and precision treatments.

Other Small ncRNA Classes

Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that primarily guide chemical modifications of other RNAs, mainly ribosomal RNAs, transfer RNAs and small nuclear RNAs. There are two main classes, the C/D box snoRNAs, which are associated with methylation, and the H/ACA box snoRNAs, which are associated with pseudouridylation.

Y non-coding RNAs were initially found in the cytoplasm of mammalian cells. There are four non-coding Y RNAs in humans: hY1, hY3, hY4 and hY5 RNA. Y RNA fragments are not involved in the miRNA pathway but they are essential factors for the initiation step of chromosomal DNA replication in human cell nuclei. The mechanism is poorly understood but is thought to be mediated by interactions with chromatin and transcription initiation proteins.

Small nuclear ribonucleic acid (snRNA) are found within the splicing speckles and Cajal bodies of the cell nucleus in eukaryotic cells. The length of an average snRNA is ~150 nucleotides. Their primary function is the processing of pre-messenger RNA in the nucleus. They also aid the regulation of transcription factors (7SK RNA) or RNA polymerase II (B2 RNA) and telomere maintenance.

Circular RNAs (CircRNAs) are a family of naturally occurring endogenous ncRNAs with widespread distribution and diverse functions. These ~100 nucleotides long, single-stranded RNA molecules form a circle through covalent binding. CircRNAs mainly arise from the exons of protein-coding genes but they can also be derived from introns, untranslated regions, intergenic loci and antisense sequences of known transcripts. CircRNAs are common in the eukaryotic transcriptome and abundant in exosomes. CircRNAs show a high sequence conservation with specific expression in various tissues during different developmental stages. Some circRNAs can interact with miRNAs and can function as miRNA sponges in mammalian cells. CircRNAs are becoming increasingly important in medicine by serving as biomarkers for non-invasive diagnosis of atherosclerosis, neurodegenerative diseases and cancers.

Gene Mutations and Inheritance

Any permanent heritable change in the sequence of genomic DNA is termed a *mutation*.

Classes of Gene Mutations

Fifty percent of all disease-causing mutations are *missense*, which are caused by a single nucleotide substitution

(*point mutation*) in the DNA coding sequence of a gene that results in the replacement of one amino acid by another in the final protein product. Nucleotide changes that involve the substitution of one purine for the other (A for G or G for A) or one pyrimidine for the other (C for T or T for C) are termed *transitions*. The replacement of a purine for a pyrimidine (or vice versa) is a *transversion*. Missense mutations are often referred to as *non-synonymous* mutations, whereas point mutations that do not alter the amino acid in the final protein product are referred to as *synonymous* mutations. Although the latter were largely ignored since they were considered to have no functional consequences, there is a growing realization that they can be associated with disease by affecting the stability of the mRNA, mRNA folding, translation fidelity and miRNA–mRNA interaction or by creating novel RNA splice sites. More than 50 human diseases are associated with synonymous mutations including Crohn's disease, Treacher Collins syndrome and Crouzon syndrome.

A point mutation in a DNA coding sequence that results in the replacement of an amino acid codon to one of the three termination codons is termed a *nonsense mutation*. Depending on its position, the resulting transcript is predicted to be recognized by the nonsense-mediated decay surveillance complexes and degraded. If this does not occur, the resulting truncated protein is usually unstable and degraded. Ten percent of all disease-causing mutations are nonsense mutations, which may affect the processing of RNA. For introns to be excised from unprocessed RNA and the exons spliced together to form a mature mRNA requires a specific nucleotide sequence located at the exon–intron (5' donor site) or the intron–exon (3' acceptor site) junctions. Mutations that affect these required bases at either the splice donor or acceptor site interfere with (and in some cases abolish) normal RNA splicing at that site. A second class of splicing mutations involves intron base substitutions that do not affect the donor or acceptor site sequences themselves. This class of mutations creates alternative donor or acceptor sites that compete with the normal sites during RNA processing. Thus, at least a proportion of the mature mRNA in such cases may contain improperly spliced intron sequences.

Mutations can also be caused by the insertion, inversion, translocation or deletion of DNA sequences. This may involve only a single base pair or up to several million base pairs. *Frameshift mutations* occur when small deletions or insertions occur within coding sequences and involve a number of bases that are not a multiple of 3. These generate a different sequence of codons from the point of the insertion or deletion and usually generate a downstream termination codon.




Figure 1.2 Symbols commonly used for creating pedigree charts.

Another form of mutation is *gene conversion*, a process by which one DNA sequence replaces a *homologous* sequence so that the sequences become identical after the conversion event. Gene conversion can be allelic, meaning that one allele of the same gene replaces another allele, or ectopic, meaning that one *paralogous* DNA sequence is converted to another. Gene conversion plays an important role in congenital adrenal hypoplasia due to mutations involving the *CYP21A2* gene, which is located on chromosome 6p21.3, 30 kb from the *CYP21A1P* pseudogene. Both *CYP21A2* and *CYP21A1P* show sequence identity of 98% between exons and 96% between introns. The high sequence identity and close proximity of *CYP21A2* and *CYP21A1P* can generate gene conversion that results in the transfer of deleterious mutations from the pseudogene to *CYP21A2*. It is estimated that 25% of all disease-causing mutations are due to deletions or insertions.

Patient and Family History

A detailed patient and family history and thorough clinical and biochemical investigation are essential to

understand if the disorder follows one of five basic modes of inheritance for single-gene diseases or if the inheritance pattern follows a more complex inheritance with incomplete penetrance or variable expressivity. The family history should include the drawing of the pedigree where individuals are represented by symbols (usually circles for female and squares for male), solid to indicate someone affected by a trait and unfilled for unaffected. Figure 1.2 illustrates some of the conventions followed in constructing pedigrees. A detailed pedigree analysis can reveal the inheritance patterns in a family. Pedigree analysis is also useful for analysing populations with limited progeny data from multiple generations.

Mendelian Inheritance Patterns

The basic laws of inheritance are important to understand patterns of disease transmission. Single-gene or monogenic diseases are usually inherited in one of several patterns depending on the location of the gene in the genome or whether one or two copies of the gene are needed for normal biological activity. The five modes of inheritance for single-gene diseases are *autosomal*

Table 1.3 Types of inheritance and their associated family history.

Type of inheritance	Family history pattern
Autosomal dominant	Individuals carrying one mutated copy of the gene will be affected by the disease. Each affected person usually has one affected parent, although <i>de novo</i> mutations occur. Usually occurs in every generation of the family
Autosomal recessive	Individuals carrying two mutated copies of the gene will be affected. Parents are usually unaffected and each must carry a copy of the mutated gene (carriers). Usually not seen in every generation
Mitochondrial	Maternally inherited. Both males and females can be affected. Can appear in every generation of a family
X-linked dominant	Females are more frequently affected than males. Fathers cannot pass on X-linked traits to their sons
X-linked recessive	Males are more frequently affected than females. Affected males are often seen in each generation. Both parents of an affected daughter must be carriers. Only the mother must be a carrier of an affected son

dominant, autosomal recessive, X-linked dominant, X-linked recessive and *mitochondrial inheritance* (Table 1.3). Single-gene disorders affect 2% of the population sometime during a lifetime.

Single-gene disorders are dominant or recessive. A dominant phenotype is expressed in both homozygotes and heterozygotes for a mutant allele, whereas a recessive phenotype is expressed only in homozygotes for the mutant allele. Most dominant disorders are rare and usually seen in the heterozygous state. Thus approximately one-half of offsprings will inherit a dominant trait. Homozygotes for dominant traits have usually a more severe phenotype or fail to survive. Many autosomal dominant mutations result in *haploinsufficiency*, which occurs when the single functional copy of the gene does not produce enough gene product to produce a wild-type phenotype.

A *dominant negative mutation* dominantly affects the phenotype by means of a defective protein or RNA molecule that interferes with the function of the normal gene product in the same cell. Most recessive disorders are due to mutations that result in the reduction or elimination of the function of the gene product and are termed *loss-of-function* mutations. Examples include 5-alpha reductase deficiency, due to autosomal recessive mutations in the *SRD5A2* gene, and congenital adrenal hyperplasia, due to homozygous mutations in the *CYP21A2*, *CYP11B1* or *CYP11A1* genes.

The majority of loci on the X chromosome show *X-linked inheritance* because they participate in meiotic recombination only during female gametogenesis, when there are two X chromosomes; they cannot recombine with the Y during male gametogenesis. Males have a single X and are therefore *hemizygous* with respect to X-linked genes. 46,XY males are never heterozygous for alleles at X-linked loci, whereas females can be heterozygous or homozygous at X-linked loci. To compensate for the double complement of X-linked genes in females, alleles for most X-linked genes are expressed from only one of the two X chromosomes in any given cell.

A *sex-limited trait* is a phenotype expressed in only one sex, although the gene that determines the trait is carried by both sexes and therefore autosomal. This is an on or off phenomenon. Sex-limited genes cause the two sexes to show different phenotypes, despite having the same genotype. They are responsible for sexual dimorphism, a phenotypic (directly observable) difference between males and females of the same species (e.g. lactation). This is not to be confused with *sex-linked traits*, which is the phenotypic expression of an allele present on the sex chromosome of the individual. A classic example is male-limited precocious puberty, an autosomal dominant disorder in which affected boys develop secondary sexual characteristics and undergo an adolescent growth spurt at about 4 years of age. In some families, the phenotype is due to mutations in the gene that encodes the receptor for luteinizing hormone (*LCGHR*). A *sex-influenced trait* refers when the expressivity of the phenotype is influenced by the sex, for example, body and facial hair.

For many phenotypes the mode of inheritance may depend on the gene involved. Non-syndromic disorders of testis determination, 46,XY complete or partial gonadal dysgenesis, can be inherited in a number of different ways that include sex-limited autosomal recessive (e.g. *DHH*), sex-limited autosomal dominant with variable expressivity and incomplete penetrance (e.g. *NR5A1*), Y-linked (*SRY*) or X-linked (hemizygous duplication of *NROB1*).

Non-Mendelian Inheritance Patterns

Mitochondrial DNA (mtDNA) molecules, are present in tens to thousands of copies per cell. If a cell contains mitochondria that contain only a pure population of mutant mtDNA, it is termed *homoplasmy*. Alternatively, if the cell has mitochondria, some with and some without mutation, it is termed *heteroplasmy*. Disorders involving mtDNA mutations are characterized by maternal inheritance. Sperm mitochondria are eliminated from the embryo, so that mtDNA is always inherited from the mother. Thus, all the children of a female who is

homoplasmic for a mtDNA mutation will inherit the mutation, whereas none of the offspring of a male carrying the same mutation will do so. mtDNA mutations cause human diseases that often involve the central nervous and musculoskeletal systems. The proportions of normal and mutant mtDNA in the cells making up different tissues often result in incomplete penetrance of the phenotype, variable expression and *pleiotropy*.

Amplification of a repeat sequence is observed in disorders such as Huntington disease and fragile X syndrome. In the former, a simple trinucleotide repeat is located in the coding region and in a transcribed but untranslated region of the *FRM1* gene in the latter. *Trinucleotide repeat* disorders often show a *parent-of-origin* effect. Large expansions of the CAG repeat that cause juvenile Huntington disease are generally of paternal origin, whereas large expansions of the CGG repeat in fragile X syndrome are often of maternal origin.

Mosaicism is the presence of at least two cell lines that differ genetically but are derived from a single zygote in an individual or a tissue. Mosaicism can be categorized as somatic and/or germline. Mosaicism for numerical or structural abnormalities of chromosomes is clinically important and somatic mutations are recognized as a major contributor to many types of cancer. Somatic mosaicism refers to population of cells that carry a mutation in some tissues of the body but not in the gametes, whereas the cells carrying the mutation may be restricted to the gamete lineage in germline mosaicism. In some individuals both somatic lineages and the germline may be affected. 45,X/46,XY is a disorder of sex development associated with sex chromosome aneuploidy and mosaicism of the Y chromosome associated with highly variable clinical phenotypes, ranging from partial virilisation and ambiguous genitalia at birth to individuals with completely male or female gonads.

Common Disorders with Complex Inheritance Patterns

Many common disorders such as myocardial infarction, Alzheimer disease and diabetes do not follow Mendelian inheritance patterns seen in single gene disorders. They result from complex interactions between a number of genetic and environmental factors and follow a multifactorial or complex inheritance pattern.

Complex phenotypes can be divided into *qualitative* and *quantitative traits*. A qualitative trait is the presence or absence of the disorder, whereas a quantitative trait is a measurable physiological or biochemical aspect of the disorder such as the body mass index in obesity.

Familial aggregation of a common phenotype does not always mean that the cause must be genetic. Family members may develop a disorder by chance since, as well

as genes, family members often share a common environment, diet, socio-economic status and culture. The familial aggregation of a disorder can be measured by comparing the frequency of the disorder in the relatives of an affected proband with its frequency in the general population. The more common a disorder in the general population, the more likely it is that the familial aggregation may be a coincidence.

Another approach to determine familial aggregation is case–control studies. Patients with the disorder are compared with carefully chosen control individuals who do not have the disorder. Often this is a spouse since they usually match the case in terms of age, ancestry (previously referred to as ethnicity) and environment. These types of studies are subject to errors that include ascertainment biases and failure to correctly match case–control subjects. Control individuals should differ from cases only in their disease status. All other factors should be matched. If they are not matched, a case–control study may find significant associations that are due to differences in, for example, ancestry rather than any relationship to the presence or absence of the disorder.

The genetic contribution to a complex disorder can be dissected by measuring allele sharing between affected and unaffected relatives. The concept is simple: when a genetic contribution is important in a disorder, the frequency of disease concordance increases as the degree of relatedness increases. Monozygotic twins (MZ) are the most extreme example as they have all their alleles in common. A first-degree relative shares $\frac{1}{2}$ of alleles, a second-degree relative $\frac{1}{4}$, and a third-degree relative $\frac{1}{8}$ and so on. One of the most common ways of separating the genetic contribution from the environment is to study MZ and dizygotic twins (DZ). DZ reared together allow the measurement of disease concordance in a similar environment, whereas MZ twins provide the opportunity to study genotypically identical individuals reared in similar or different environments. Greater disease concordance in MZ versus DZ twins is strong evidence for a genetic contribution to the disease.

Heritability was developed to quantify the role of genetic differences in determining variability of quantitative traits. It is the fraction of the total phenotypic variance of a quantitative trait caused by genes. Due to genetic differences between individuals, the higher the heritability, the greater the variability of the phenotype. Heritability measures the fraction of phenotype variability that can be attributed to genetic variation but it does not indicate the degree of genetic influence on the development of a trait of an individual.

Good examples of complex or multifactorial disorders include hypospadias and T1D. Hypospadias is one of the most common congenital disorders in males occurring in 1:200–1:300 male births. Anterior (glandular) and

middle (penile) forms comprise 70–80% and 15–20% of cases, respectively. Hypospadias shows familial clustering, with 7% of cases having affected first-, second- or third-degree relatives. The chance that a brother of an affected boy will also have hypospadias is 9–17%. Studies of family as well as twins of known zygosity have estimated the heritability of hypospadias to be 57–77%, meaning that 57–77% of the phenotypic variability can be attributed to genetic variability. Like many other common disorders, such as infertility, current data indicate that hypospadias might be monogenic in a small proportion of the families (e.g. the mutations in genes *NR5A1*, *AR*, *FGFR2* and *MAMLD1*) but that there is a multifactorial cause in the majority of cases.

T1D is a result of interplay between genetic predisposition, environmental factors and reprogramming of the immune system. The destruction of pancreatic β -cells affects the level of insulin secretion leading to disease development. Destruction of pancreatic β -cells is mediated by an altered immune response due to genetic anomalies resulting in increase of pro-inflammatory cytokines and autoreactive T and B lymphocytes. Twin studies have estimated that 88% of phenotypic variance of T1D in Finland is due to genetic factors and the remaining due to unshared environmental factors. Genome-wide association studies have identified more than 50 variants associated with increased risk for T1D. The HLA class II region has the strongest impact on T1D risk. However, more than 40 non-HLA loci that impact upon the risk of developing T1D have been identified. Many of these genes are associated with immune function including *interleukin (IL)-2Ra*, *PTN22*, *IL-10*, *CCR5* and *IL-2*.

Uniparental Disomy

Uniparental disomy (UPD) occurs when a person receives two copies of a chromosome or of part of a chromosome from one parent and no copy from the other. UPD usually arises from the failure of the two members of a chromosome pair to separate properly into two daughter cells during meiosis in the parent's germline (nondisjunction). The resulting gametes contain either two copies of a chromosome (disomic) or no copy of that chromosome (nullisomic). This leads to a conception with either three copies of one chromosome (trisomy) or a single copy of a chromosome (monosomy).

If a second event occurs by either the loss of one of the extra chromosomes in a trisomy or the duplication of the single chromosome in a monosomy, the karyotypically normal cell may have a growth advantage compared to the aneuploid cells.

A postfertilization error can also lead to UPD, by either somatic recombination or gene conversion. Two types of

UPD can be defined – uniparental heterodisomy (UPhD), where the two different alleles of the same parent are transmitted, and uniparental isodisomy (UPiD), where two identical copies of one allele of the contributing parent are present.

UPD may have clinical relevance for several reasons. For example, either *isodisomy* or *heterodisomy* can disrupt parent-specific genomic imprinting, resulting in imprinting disorders. Additionally, isodisomy leads to large blocks of homozygosity, which may lead to the uncovering of recessive genes. Uniparental inheritance of imprinted genes can result in phenotypic anomalies. Examples include Prader–Willi, Angelman and Silver–Russell syndromes. Prader–Willi syndrome, characterized by hypothalamic–pituitary abnormalities, is caused by deletion or inactivation of genes on the paternally inherited chromosome 15, while the maternal copy, which may be of normal sequence, is imprinted and therefore silenced. Angelman syndrome is a neurodevelopmental disorder caused by the loss of maternally inherited genes on chromosome 15 and paternal imprinting. Silver–Russell syndrome is a clinically heterogeneous disorder characterized by severe *in utero* growth restriction and poor postnatal growth, body asymmetry, irregular craniofacial features and several additional minor malformations. The etiology is complex and current evidence strongly implicates imprinted genes. Approximately half of all patients exhibit DNA hypomethylation at the *H19/IGF2* imprinted domain; around 10% have maternal UPD of chromosome 7.

Penetrance and Expressivity

Some disorders are not expressed in an individual, even though the individual carries the mutation causing the phenotype in other members of the family. This is termed *penetrance*, defined as the probability that a gene mutation will have a phenotypic expression. Penetrance is an all or nothing concept. If only a proportion of people carrying the genotype display the phenotype, the trait is said to show incomplete penetrance. If all carriers show the phenotype, then the trait is said to have complete or full penetrance. For example, familial cases of central precocious puberty show reduced or incomplete penetrance.

Expressivity refers to the severity of the phenotype in different individuals carrying the same disease-causing genotype. If the severity of the phenotype differs in people with the same disease-causing genotype, the phenotype shows *variable expressivity*. Disease expressivity includes age of onset, rate of progression, severity and the manifestation of other comorbidities. There are numerous examples of studies of non-identical twins who share the same environment and carry the same disease-causing genotype yet display distinct phenotypes.

This suggests that genetic factors are acting as modifiers of the phenotype. The effect of one gene or allele on the phenotypic outcome of a second gene or locus is termed epistasis, genetic interaction, digenic inheritance, oligogenic inheritance or genetic modifier. Although these are essentially synonyms, there are important distinctions that can be drawn.

If a mutation in the primary gene is both necessary and sufficient to cause disease, the presence of an allele at a second gene has a purely modifying role on the severity of the phenotype. Digenic or oligogenic inheritance is termed when alleles at two (di-) or more (oligo-) genes are required to manifest the pathology. In practice this distinction is often blurred. It is important to note that variability in the expression of the phenotype could also be due to environmental factors, perhaps interacting with genetic variants. Examples of genetic modifiers include variation in an interacting protein partner or, if the protein is a DNA-binding transcription factor, variation in target binding sequences. An example of variable expressivity is the phenotype associated with mutations in the *NR5A1* gene. Here, mutations involving the same amino acid change are associated with 46,XY complete gonadal dysgenesis in some individuals and infertility in others. Digenic and, more rarely, oligogenic inheritance has been reported in individuals with central hypogonadotropic hypogonadism (CHH). Where the causal mutation has been identified, over 80% of patients with CHH have a monogenic cause but ~12% have digenic and 2.5% oligogenic inheritance.

Human Populations and Genetic Variation

Overview of Human Genetic Variation

Mendelian phenotypes result from mutations that alter the function, localization and/or the presence of a protein. Even though protein-coding sequences comprise only around 2% of the human genome, linkage analyses on pedigrees with various disorders have shown that the vast majority of disease-causing mutations are variants that directly impact protein expression or function. This excludes ascertainment bias. Overall, clinically recognized Mendelian phenotypes occur in ~0.4% of all live births and 8% of live births have a genetic disorder recognizable by early adulthood. The Human Genome Project and subsequent *annotation* efforts have established that there are around 19,000 predicted protein-coding genes in humans. The consequences of germline mutations (single nucleotide variants [SNVs] and copy number variants [CNVs]) are known for more than 2300 of these genes. Around 3300 genes have been implicated in

Mendelian disorders and this figure is growing at around 300 per year.

Humans are 99.9% identical with respect to their DNA sequence. A typical human genome from an apparently healthy individual differs from the reference genome at 4.1–5 million sites (>99.9% SNVs or indels) and carries 300–600 non-synonymous mutations that are found in <1% of the general population (minor allele frequency, MAF<0.01). This includes around 150 mutations that are not (yet) present on any of the public variation databases and that are a combination of *de novo* or family or community-specific DNA variants. All of us inherit about 100 likely loss-of-function or nonsense variants from our parents and around 25–30 variants per genome that have been reported to be associated with rare diseases (ClinVar: <http://www.ncbi.nlm.nih.gov/clinvar>).

One of the surprises from the large amount of genomic data generated from healthy control populations in recent years, such as the 1000 genomes project, is the relatively high prevalence of mutations that have previously been reported as causing severe disease. This suggests that a combination of incomplete penetrance, a false assignment of pathogenicity or a wide range in the expressivity of the phenotype may be more common features of disease mutations than is generally appreciated.

Genetic variation in the general human population can be interrogated using dbSNP (<http://www.ncbi.nlm.nih.gov/SNP>) or the Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org>). The Exome Aggregation Consortium (ExAC) data set contains exome sequence data from more than 60,000 individuals with an assigned geographic ancestry. Approximately 60.9% of the samples in the ExAC reference cohort are of European ancestry, compared with 13.7% of South Asian ancestry, 9.6% of Latino ethnicity, 8.6% of African (African American) ancestry and 7.2% of East Asian ancestry.

Allele Frequencies Differ in Different Populations

Although most variants are common across human populations, rare gene variants can show markedly different patterns across different human communities. The 1000 genomes project established that there are several hundred thousand SNVs that show considerable differences in allelic frequencies in geographically and ancestry distinct populations. There are several explanations for this. Local populations may have adapted to their specific environments and genetic variants that facilitated this adaptation were selected by evolution (positive selection), which could explain the high frequency of mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene in individuals of European ancestry. Carriers of *CFTR*

mutations may have had more resistance to cholera and other dehydrating intestinal disorders or are more resistant to contracting tuberculosis.

The demographic history of a population can also have a dramatic impact on allele frequencies in modern populations. Migration can change allele frequency by the process of gene flow, defined as the slow diffusion of genes across a barrier. This usually involves a large population and a gradual change in gene frequencies. The genes of migrant populations with their own characteristic allelic frequencies are gradually merged into the gene pool of the population into which they have migrated. Historically small and/or isolated populations or populations that experienced a population bottleneck can also effect allelic frequencies. Tay–Sachs disease in Ashkenazi Jews is an example, where a Tay–Sachs mutation arose by chance in a small breeding population and led to a *founder effect*.

Chance events can have a much greater effect on allele frequencies in a small population than in a large one. If the population is small, random effects, such as increased fertility or survival of the carriers of a mutation that occurred for reasons *unrelated* to carrying the mutant allele, may cause the allele frequency to change from one generation to the next. This is termed *genetic drift*. Whatever the mechanism, large-scale sequencing projects are showing that disease-causing alleles at relatively high frequencies in specific populations and communities as well as rare variants may be an important contributor to common diseases. This has an important impact on the clinical work-up of a patient, where it is essential to determine the ancestry of the affected individual.

Copy Number Variation (CNV)

Human populations also show extensive structural polymorphism, both deletions and duplications of chromosomal segments and, consequently, in the number of genes in these segments. Approximately two-thirds of the human genome is composed of repeats and 4.8–9.5% of the genome contributes to CNVs. Indeed, CNVs are thought to account for ~1% of the variation between two individuals. In contrast, SNVs are thought to account for ~0.1% of the variation. CNVs can arise both meiotically and somatically and can therefore contribute to variation between identical twins as well as variation between different organs and tissues of the same individual.

Smaller deletions and insertions (typically >50 kb) can be detected by comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) analysis. MLPA is a variation of the multiplex polymerase chain reaction. For a short sequence of

target DNA, two adjacent probes are designed to contain the forward and reverse primer sequence, respectively. In addition, one or both probes contain a stuffer sequence of which the length can be varied during the experiment. The probes are hybridized against the target DNA and subsequently ligated. Only if ligation happened does a functional PCR strand appear, so that amplification only happens if target DNA is present in the sample. The amount of PCR product is proportional to the amount of target DNA present in the sample, making the technique suitable for quantitative measurements.

Comparative genomic hybridization is a molecular cytogenetic method for analysing CNVs relative to ploidy level in the DNA of a test sample compared to a reference sample. Classically this was performed by differentially labelling a reference and test genome and hybridizing to an immobilized substrate such as a microarray. The fluorescence ratios provide a representation of the relative DNA CNV. Today, this is performed by a combination of hybridization of unlabelled DNA to target oligomers and enzymatic single-base extension to incorporate a labelled nucleotide for assay read-out but this is likely to be superseded by whole genome sequencing (WGS) in the near future.

There are still many hurdles in the clinical interpretation of CNVs. They are relatively common and there are many examples of known pathogenic CNVs exhibiting reduced penetrance and/or variable expressivity. This can result in a more severely affected child, who has inherited a CNV from a seemingly normal parent. The 22q11.2 deletion (del) syndrome is a classic example of this. In general, large, rare recurrent deletions and duplications are straightforward to interpret because of considerable genetic and phenotypic evidence. Typically, in a large multi-centre clinic, 15–20% of cases with developmental delay are associated with diagnostic findings from whole genome chromosomal microarray (CMA) analysis. Among these diagnostic cases, many rare CNVs are detected for which the potential functional significance is unknown and they are referred to as variants of uncertain (or unknown) significance (VUS). It is important to bear in mind that ~100 genes can be completely deleted from the human genome without phenotypic consequences.

The major challenge in this field is the detection and interpretation of small (>1–5 kb) rearrangements. These are generally too small to be detected by conventional microarrays but can be detected by WGS. Current data indicate that each individual carries many thousands of these small CNVs. Because of the absence of information in public databases on these small rearrangements, the interpretation of these small variants is challenging. CNVs are of considerable importance in pediatric endocrinology. A considerable proportion of individuals with